Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
Completed · Phase 3 · NCT03275285
Conditions: Plasma Cell Myeloma
At a glance
- Research payments reported, 2025
- $6,768
- U.S. investigators named
- 0
- Sites paid
- 1
- Planned or actual enrollment
- 302
About the trial
- Sponsor
- Sanofi
- Tested
- isatuximab SAR650984 (drug), carfilzomib (drug), dexamethasone (drug)
- Dates
- Started 2017-10-25; completion 2025-01-03
- Results posted
- Yes
The purpose of this study it to compare the efficacity of isatuximab when combined to carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with multiple myeloma already treated with 1 to 3 prior lines of therapy.
From ClinicalTrials.gov, last updated 2026-02-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $6,768 in research payments for this study in 2025 (1 payments).
Products named: Sarclisa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.